页数:22页文件大小:181.5 KB来源: 药理学ppt课件
本课件为药理学课程中的《抗中枢退行性疾病药》,围绕抗中枢退行性疾病药、抗帕金森病药、The normally、一、左旋多巴及其增效剂等部分展开,逐页梳理概念、机制与临床应用要点,适合预习、课堂对照与考前复习。
抗中枢退行性疾病药
抗帕金森病药
PARKINSONISM (Paralysis Agitants) Parkinsonism is characterized by a combination of rigidity,bradykinesia, tremor, and postural instability that can occur fora wide variety of reasons but is usually idiopathic. Thepathophysiologic basis of the idiopathic disorder may relate toexposure to some unrecognized neurotoxin or to theoccurrence of oxidation reactions with the generation of freeradicals. Studies in twins suggest that genetic factors may alsobe important, especially when the disease occurs in patientsunder age 50. Parkinson's disease is generally progressive,leading to increasing disability unless effective treatment isprovided.
The normally high concentration of dopamine in thebasal ganglia of the brain is reduced in parkinsonism,and pharmacologic attempts to restore dopaminergicactivity with levodopa and dopamine agonists havebeen successful in alleviating many of the clinicalfeatures of the disorder. An alternative butcomplementary approach has been to restore thenormal balance of cholinergic and dopaminergicinfluences on the basal ganglia with antimuscarinicdrugs. The pathophysiologic basis for thesetherapies is that in idiopathic parkinsonism,dopaminergic neurons in the substantia nigra thatnormally inhibit the output of γ-aminobutyric acid(GABA)ergic cells in the corpus striatum are lost.
Schematic representation of thesequence of neurons involved inparkinsonism. Top:Dopaminergic neurons (color)originating in the substantia nigranormally inhibit the GABAergicoutput from the striatum, whereascholinergic neurons (gray) exert anexcitatory effect. Middle:In parkinsonism,there is a selective lossofdopaminergic neurons (dashed, color).
Fate of orallyadministered levodopaand the effect ofcarbidopa, estimatedfrom animal data. Thewidth of each pathwayindicates the absoluteamount of the drugpresent at each site,while the percentagesshown denote therelative proportion of theadministered dose. Thebenefits ofcoadministration ofcarbidopa includereduction of the amountof levodopa diverted toperipheral tissues and anincrease in the fractionof the dose that reachesthe brain.
一、左旋多巴及其增效剂 1.左旋多巴(L-dopa)药理作用与机制左旋多巴可使 80% PD 病人症状明显改善。其中 20%的病人可恢复到正常运动状态。起病初期用药疗效更为显著,用药后患者感觉良好,抑制和淡漠症状改善,服药后先改善肌强直和运动迟缓,后改善肌震颤,由于情绪好转,能关心周围环境,思维清晰敏捷,听觉口语学习能力明显改善,生活质量明显提高。
体内过程口服后主要在小肠经主动转运系统而迅速吸收。进入中枢量不到 1%,99%在外周经脱羧换化为 DA 是引起不良反应的主要原因。因此,提出与外周多巴脱羧酶抑制剂合用达到增效,减少不良反应,还可减少左旋多巴的用量。
临床应用 1.帕金森病治疗广泛用于各种类型 PD 病人,运动障碍症状不明显者一般不用。对抗精神病药物所致锥体外系症状无效。病人长期用药效果有较大个体差异。服药 6 年后,约半数病人失效。
2.肝昏迷辅助治疗肝昏迷病人,由于肝功能障碍,血中苯乙胺、酪胺升高,在神经细胞内经β-羟化酶作用生成苯乙醇胺和章胺(伪递质)妨碍正常神经功能。用左旋多巴后,转化为 NA 恢复正常神经功能,病人逐渐转为清醒。鱼
不良反应大多是由于左旋多巴在体内生成 DA 所致。
1.胃肠道反应厌食、恶心、呕吐、腹部不适。是由于 DA 兴奋延脑催吐化学感受区所致。继续治疗,由于产生耐受性,胃肠道反应可减轻。
2.心血管反应部分病人出现体位性低血压反应,表现头晕,偶见晕厥。少数病人心律失常(DA 兴奋心脏β1 受体)。
3.不自主异常运动如咬牙、吐舌、点头、做怪相及舞蹈样动作,发生率约 40~80%,多在长期用药后出现,主要是由于 DA 补充过度,须减量。少数病人长期用药后,可出现“开关现象”,表现为突然多动不安(开),转为全身产生强直不动(关),二者交替出现,机制尚无完满解释。
4.精神障碍与 DA 过度兴奋中脑一边缘系统 DA 受体有关。
2.外周多巴脱羧酶抑制剂卡比多巴(Carbidopa)、苄丝肼(benserazide)外周多巴脱羧酶抑制剂,不易通过血脑屏障。单独应用对 PD 无治疗作用,主要与左旋多巴按一定比例制成复方左旋多巴制剂供临床应用,可增加血和脑内 L-dopa 达 3 ~ 4 倍。信尼麦(sinemet,心宁美)左旋多巴:卡比多巴=10:1(100mg:10mg)复方苄丝肼(美多巴,Madopar)左旋多巴:苄丝肼=4∶1(100mg∶25mg)
3. COMT 抑制剂 L-dopa 代谢有两条途径:L-dopa DA 3-OMD(3-O-甲基多巴)而 3-OMD 又可与 L-dopa 竞争转运载体而影响 L-dopa 的吸收和进入脑组织(生物利用度降低)-co2COMT
硝替卡朋(nitecapone)托卡朋(tocapone)安托卡朋(entocapone)可增加纹状体中 L-dopa 和 DA。当与卡比多巴合用时,只抑制外周 COMT,增加 L-dopa 生物利用度,而不影响脑内 COMT(不易通过血脑屏障)。
抗老年性痴呆药 Downsized Target A tiny protein called ADDL could be thekey to Alzheimer's Scientific American 2004
Scientists have long suspected that the proteinclumps and tangles identified by Alois Alzheimer in1907 somehow cause the disease that bears hisname, probably by killing neurons. Now someresearchers are blaming a much smaller form ofprotein, one that apparently produces memorydeficits merely by binding to neurons and disruptingtheir ability to transmit signals. The search has begunfor an antibody that would destroy these tinyproteins--or ADDLs--thereby preventing the onset of Alzheimer's disease and possibly even reversing theearly symptoms.
The discovery of ADDLs explains glaringanomalies in the conventional thinking about Alzheimer's, which holds that fragments of amyloidprecursor protein, produced by normal neurons,aggregate into sticky, insoluble plaques that damageneurons. The problem with this theory is that virtuallyevery older person carries some amyloid plaque, butonly a few develop Alzheimer's. Conversely, those with Alzheimer's often have relatively few plaques. Anotherproposed culprit is the presence of tangles of tauprotein, which form inside neurons and coincide withthe collapse of microtubules that support the cell bodyand transport nutrients. The tau tangles correlatemuch better with the disease but tend to appear later,suggesting that they are a consequence, not a cause.
In 1994 Caleb E. Finch, aneurogerontologist at the University of Southern California, attempted to createamyloid plaque by mixing a solution of amyloidprecursor protein fragments with clusterin, asubstance produced at higher levels in thebrains of people with Alzheimer's. Theclusterin did not trigger the formation ofamyloid plaques, but the resulting solutionprofoundly disrupted the ability of the neuronsto transmit signals.
Finch reported this finding to Grant A. Krafft and William L. Klein, two colleagues at Northwestern University, who set out to discover what was in thesolution. Using an atomic-force microscope, theyobtained extraordinary pictures of globules no one hadever seen. "They looked like little marbles," Krafftrecalls. "It turned out these globules contained only afew of the amyloid peptide building blocks, whereasthe long fibrils contained thousands, if not millions, ofthese subunits." The three scientists decided to callthe substance ADDL, which stands for amyloid beta-derived diffusible ligand. (The molecule is derivedfrom amyloid precursor protein; it diffuses throughoutthe brain instead of aggregating into fixed plaques; asa ligand, it attaches to receptors on neurons.)
Klein developed an antibody that revealed how ADDLsattach to dendrites in the hippocampus, thereby disruptingsignals needed to produce short-term memories. And lastsummer Klein, Krafft, Finch and their colleagues found hugequantities of ADDLs in postmortem brains from people with Alzheimer's, whereas brains from normal patients were virtuallyfree of ADDLs. What is more, they discovered that neurons ofmice functioned normally once the ADDLs were removed. The obvious solution to treat Alzheimer's disease, in Krafft's opinion, is to remove the ADDLs or prevent them fromforming. Attempts to eradicate amyloid plaques are misguided,he believes, and any attempt to intervene after neurons havestarted to die comes too late to do much good. "It's pretty clearto me that we're wasting about 90 percent of the Alzheimer'sresearch budget on things that are worthless," he says.
While crafting their theory, Krafft, Klein and Finch acquired patent rights to ADDLs and formedtheir own corporation, Acumen Pharmaceuticals,which recently formed a partnership with Merck. "Bypartnering with Merck, Acumen can get the antibodyand vaccine products to market much faster than if wetried to do it by ourselves," Krafft explains. Merck has committed up to $48 million to Acumen for the right to develop an antibody against Alzheimer's and another $48 million if it succeeds inbringing to market a viable vaccine. That money, plusfunding from other investors, will enable Acumen todevise three other ADDL-based strategies forpreventing Alzheimer's, as well as diagnostic tests thatwould reveal early signs of the disease.
下载地址:{{downurl}}
{{{a}}}
{{#b}}{{{b}}}
{{/b}} {{/title}} {{#nolog}}登陆注册
{{/nolog}} {{#djsx}}点我刷新
{{/djsx}} {{#gocz}} {{/gocz}} {{#ffqr}} {{/ffqr}}